Clinical trials: Non-small Cell Lung Cancer Unresectable
Lung Cancer
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
This purpose of this study is to evaluate the role of gemcitabine and docetaxel, a well tolerated chemotherapy regimen in the treatment of advanced non-small cell lung cancer (NSCLC), in combination with a novel agent cetuximab.
- Trial name
- NCT00193453
- Testing
- Gemcitabine, Docetaxel, Cetuximab
- Where
- 10 sites in United States
- Volunteers
- 69 people
- Sponsor
- SCRI Development Innovations, LLC
Non-Small Cell Lung Cancer
Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)
The purpose of this study is to find out what effects, good and/or bad, proton radiation at a higher tumor dose (and lower normal surrounding lung dose) combined with standard chemotherapy has on lung cancer.
- Trial name
- LU02 (NCT00881712)
- Testing
- PET positive nodal disease measuring 15 mm or greater, PET positive nodal disease measuring less than 15 mm, Patients considered resectable
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Florida
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00005838
- Testing
- shark cartilage extract AE-941, cisplatin, vinorelbine tartrate
- Where
- United States
- Volunteers
- 756 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer, Colorectal Carcinoma
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
- Trial name
- NCT06218914
- Testing
- NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell-Lung
Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer
The purpose of this study is to evaluate the safety of I-PDT with Temoporfin for patients with Non-Resectable Non-Small-Cell Lung Cancer (NR-NSCLC).
- Trial name
- NCT01637376
- Testing
- Temoporfin
- Where
- United States
- Sponsor
- University of Arkansas
Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with…
- Conditions
- Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
- Trial name
- NCT07154290
- Testing
- Ubamatamab, Marlotamig, Sarilumab
- Where
- 18 sites in United States
- Volunteers
- 300 people
- Sponsor
- Regeneron Pharmaceuticals
Non-small Cell Lung Cancer Metastatic
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer
This single arm study will assess the efficacy and safety of erlotinib + gemcitabine in chemotherapy-naive participants with unresectable, advanced and/or metastatic non-small cell lung cancer.
- Trial name
- NCT00701558
- Testing
- Erlotinib, Gemcitabine
- Where
- Romania
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).
- Trial name
- NCT04951635
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic…
- Trial name
- SKYSCRAPER-01 (NCT04294810)
- Testing
- Atezolizumab, Tiragolumab
- Where
- 134 sites in United States, Australia and 21 more
- Volunteers
- 620 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Endometrial Cancer
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
RATIONALE: Metformin and temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Breast Cancer, Endometrial Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00659568
- Testing
- metformin hydrochloride, temsirolimus
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- London Health Sciences Centre
Lung Cancer
Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00075374
- Testing
- docetaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Advanced Non Small Cell Lung Cancer
Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC
The aim of the study was to investigate the efficacy of Toripalimab Combined with Double Platinum Based Chemotherapy for Initially Unresectable Non-driver Gene Mutation Non-small Cell Lung Cancer.
- Trial name
- TOGATHER (NCT04144608)
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yongchang Zhang
NSCLC Stage III, Ensartinib
Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC
The PACIFIC study established the standard of care for immunotherapy consolidation after chemoradiotherapy (CRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC).
- Conditions
- NSCLC Stage III, Ensartinib, Chemoradiotherapy, ALK
- Trial name
- NCT07235306
- Testing
- Ensartinib 225mg
- Volunteers
- 45 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Thoracic Solid Malignant Tumor
Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
To evaluate the safety and efficacy of Boron Neutron Capture Therapy (BNCT) in patients with recurrent thoracic solid tumors that are difficult to treat with standard radiation therapy or drug therapy and are unresectable.
- Trial name
- NCT06603987
- Testing
- BNCT, ［18F］FBPA
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Stella Pharma Corporation
Lung Cancer
Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003387
- Testing
- carboplatin, chemotherapy, paclitaxel
- Where
- 47 sites in United States
- Volunteers
- 366 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as carboplatin, paclitaxel, cisplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00738452
- Testing
- high performance liquid chromatography, pharmacological study, radionuclide imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Stage III Non-small Cell Lung Cancer
Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC
Consolidation immunotherapy of immune checkpoint inhibitor (ICI) following chemoradiotherapy (CRT) is the current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) as it improves…
- Trial name
- NCT04984148
- Testing
- CT
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Guangdong Provincial People's Hospital
Unresectable Stage III Non-small-cell Lung Cancer
Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer
For unresectable stage III (8th TNM) non-small cell lung cancer, chemoradiotherpay plus immunotherapy is recommended by PACIFIC trial.
- Trial name
- NCT06591910
- Testing
- Chemoimmunotherapy, Surgery, Radiation
- Volunteers
- 50 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer
Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer
The purpose of this study is to determine the optimal dose of nab-paclitaxel to be safely administered in combination with pembrolizumab in patients with advanced inoperable non-small cell lung cancer.
- Trial name
- URCOH-PMS-001 (NCT02733250)
- Testing
- Pembrolizumab, Nab-Paclitaxel
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)